Table of Contents
A probability-based, nationally representative RAND survey of 10,122 US adults estimates that roughly 10 million Americans microdosed psilocybin, MDMA, or LSD in 2025, representing about 3.7 percent of the adult population. The survey is observational, and the evidence on benefit and safety remains mixed.
- Microdosing is no longer a fringe behavior. RAND’s weighted population estimates place the number of US adults who microdosed at least one psychedelic in 2025 at approximately 10 million, a scale that one expert called a mainstream public health issue.
- Psilocybin leads, but MDMA microdosing surprised researchers. Among past-year users, an estimated 69 percent microdosed psilocybin and 65 percent microdosed MDMA at least once, numbers that the lead author described as unexpected for MDMA specifically.
- Use days are heavily weighted toward small doses. Of an estimated 216 million psilocybin use days in 2025, 47 percent involved microdosing. For MDMA and LSD, the shares were 42 percent and 41 percent respectively.
- Evidence has not kept pace with practice. Commenting experts noted that long-term and chronic effects of microdosing remain unknown, and that current clinical evidence is mixed, with some controlled studies showing no benefit over placebo.
- Model
- Human
- Sample
- 10,122 US adults, probability-based nationally representative panel (approximately 97% household coverage)
- Dose
- Self-reported; microdosing defined as a subperceptual dose much lower than a hallucinogenic threshold
- Design
- Cross-sectional survey; weighted to reflect the US adult population
- Key outcome
- Approximately 10 million adults microdosed psilocybin, MDMA, or LSD in 2025, roughly 3.7% of US adults
- Main limitation
- Cross-sectional design, self-reported data, no universal definition of a microdose across participants
What the Research Examined
The 2025 RAND Psychedelics Survey is a probability-based, nationally representative cross-sectional study of 10,122 US adults, designed to capture population-level estimates of psychedelic use across 11 substances including psilocybin, MDMA, LSD, ketamine, DMT, ibogaine, and Amanita muscaria, among others. The sample was weighted to approximate the full US adult population and was funded by DAFgiving360. Lead author Michelle Priest, PhD, is a research project specialist at RAND, a nonprofit think tank in Santa Monica, California.
Participants reported both lifetime and past-year use, and microdosing was defined for the purposes of the study as taking a subperceptual dose well below the amount needed to produce hallucinogenic effects. On the basis of those weighted estimates, RAND calculated total use days per substance and then determined what share of those days involved microdosing. For anyone seeking broader context on the science and practice of microdosing, that background shapes how these population numbers should be read: high prevalence does not by itself confirm safety or efficacy.
The unweighted sample sizes for past-year users were relatively modest: 372 for psilocybin, 163 for MDMA, and 90 for LSD. Population-level figures were derived through statistical weighting. Commenting experts who were not involved in the study flagged the cross-sectional design and the absence of a standardized microdose definition as meaningful constraints on interpretation. Long-term or chronic effects of regular subperceptual dosing have not been established in controlled human research.
What the Findings Show
- Estimated microdosers, 2025.Approximately 10 million US adults microdosed psilocybin, MDMA, or LSD in 2025, representing roughly 3.7 percent of the adult population.
- Psilocybin use days.RAND estimated 216 million psilocybin use days in the past year; 47 percent of those days involved microdosing.
- MDMA and LSD microdosing share.Of an estimated 62.5 million MDMA use days, 42 percent involved microdosing. Of 21 million LSD use days, 41 percent did.
- Prevalence among past-year users.Among adults who reported any past-year use, an estimated 69 percent microdosed psilocybin, 65 percent microdosed MDMA, and 59 percent microdosed LSD at least once.
Amanita muscaria ranked third in overall use, behind psilocybin and MDMA. One commenting expert noted that its legal status under federal law, where it does not appear on the Controlled Substances Act, may lower the perceived barrier to access, while cautioning that its risk profile is less predictable and less studied than classic psychedelics. No clinical evidence currently supports its therapeutic use.
How many Americans are microdosing psilocybin or other psychedelics?
A 2025 RAND survey estimates roughly 10 million US adults, about 3.7 percent of the adult population, microdosed psilocybin, MDMA, or LSD in the past year. Among those who used any psychedelic, more than half microdosed at least once. These are population estimates from self-reported, cross-sectional data.
What This Is, and What It Is Not
This is This is a cross-sectional, self-report survey with weighted population estimates derived from modest unweighted past-year user samples.
This is not This is not a clinical trial and does not establish that microdosing is safe or effective. It does not track long-term outcomes, and no standardized microdose definition was used across participants. Nothing here constitutes medical advice.
Our Take
Numbers at this scale remind the community that curiosity about subperceptual practice has moved well beyond any single tradition or subculture. That breadth carries responsibility. When millions of people are making weekly decisions about their inner life with a substance, the conversation has to hold both the genuine promise that draws people in and the genuine unknowns that science has not yet resolved. Psilocybin as sacrament asks us to bring honesty to both.
If these numbers resonate with your own quiet experiments or your questions about what a small dose might mean in an ordinary day, we invite you to read slowly and stay grounded. The Grounding station on the Golden Path is a good place to begin: not with anticipation of what a practice will produce, but with an honest look at where you are now. The research will keep developing. So will you.
Frequently Asked Questions
What percentage of Americans microdose psychedelics?
The 2025 RAND Psychedelics Survey estimates that roughly 3.7 percent of US adults, approximately 10 million people, microdosed psilocybin, MDMA, or LSD in 2025. These are weighted population estimates from a nationally representative cross-sectional survey, not a clinical count.
Is microdosing psilocybin legal in the United States?
Psilocybin remains a Schedule I substance at the federal level. Some states, including Oregon and Colorado, have created regulated frameworks for certain uses. Individual state and local laws vary. Nothing in the RAND survey changes the federal legal status.
Does microdosing psychedelics actually work?
The evidence is mixed. Some early studies report positive effects on mood and well-being, while controlled trials, including at least one published LSD study, found no benefit over placebo. Experts who commented on the RAND survey agreed that current evidence has not kept pace with public use.
Is Amanita muscaria the same as psilocybin mushrooms?
No. Amanita muscaria contains different active compounds and carries what experts describe as a less predictable risk profile than psilocybin. It is not scheduled under the federal Controlled Substances Act and has no clinical evidence supporting therapeutic use.
What are the risks of microdosing psychedelics long-term?
Long-term effects of chronic microdosing are not established in controlled human research. Commenting experts on the RAND study stated clearly that even at low doses, the consequences of repeated use over time remain unknown. This is one of the field’s most significant open questions.
Get the Mycelium Report
We read the new psilocybin and mushroom research so you do not have to. One honest, jargon-free dispatch, delivered daily. Free to join.
May love guide the hearts of all beings.
